X |
Filing Date |
Trade Date |
Ticker |
Company Name | Insider Name | Title |
Trade Type |
Price |
Qty |
Owned |
ΔOwn |
Value |
1d |
1w |
1m |
6m |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2025-01-16 | IONS | Ionis Pharmaceuticals Inc | Swayze Eric | EVP Research | S - Sale+OE | $32.84 | -7,176 | 45,854 | -14% | -$235,678 | |||||
| D | 2025-01-16 | IONS | Ionis Pharmaceuticals Inc | Schneider Eugene | EVP, Chf Clinical Develop Ofcr | S - Sale+OE | $32.79 | -6,523 | 58,508 | -10% | -$213,889 | |||||
| D | 2025-01-16 | IONS | Ionis Pharmaceuticals Inc | O'Neil Patrick R. | EVP CLO, GC | S - Sale+OE | $32.83 | -7,360 | 61,203 | -11% | -$241,629 | |||||
| D | 2025-01-16 | IONS | Ionis Pharmaceuticals Inc | Monia Brett P | CEO | S - Sale+OE | $32.63 | -33,445 | 207,396 | -14% | -$1,091,444 | |||||
| D | 2025-01-16 | IONS | Ionis Pharmaceuticals Inc | Geary Richard S | EVP, Chief Development Officer | S - Sale+OE | $32.86 | -7,072 | 96,663 | -7% | -$232,407 | |||||
| D | 2025-01-16 | IONS | Ionis Pharmaceuticals Inc | Devers Shannon L. | EVP, Chief HR Ofc | S - Sale+OE | $32.78 | -4,267 | 15,937 | -21% | -$139,855 | |||||
| D | 2025-01-16 | IONS | Ionis Pharmaceuticals Inc | Birchler Brian | EVP, Corp, Development Ops | S - Sale+OE | $32.70 | -5,400 | 55,051 | -9% | -$176,580 | |||||
| D | 2025-01-16 | IONS | Ionis Pharmaceuticals Inc | Bennett C Frank | EVP, Chief Scientific Officer | S - Sale+OE | $32.90 | -6,752 | 90,866 | -7% | -$222,114 | |||||
| D | 2025-01-16 | IONS | Ionis Pharmaceuticals Inc | Baroldi Joseph | EVP, Chief Business Officer | S - Sale+OE | $32.70 | -4,430 | 28,088 | -14% | -$144,861 | |||||
| D | 2025-01-16 | MRSN | Mersana Therapeutics, Inc. | Mandelia Ashish | VP, Chief Accounting Officer | S - Sale+OE | $0.58 | -3,554 | 57,519 | -6% | -$2,061 | |||||
| D | 2025-01-16 | MRSN | Mersana Therapeutics, Inc. | Protopapas Anna | Dir | S - Sale+OE | $0.58 | -8,637 | 480,548 | -2% | -$5,009 | |||||
| D | 2025-01-16 | MRSN | Mersana Therapeutics, Inc. | Lowinger Timothy B | SVP, Chief Sci., Tech. Officer | S - Sale+OE | $0.58 | -8,048 | 257,673 | -3% | -$4,668 | |||||
| D | 2025-01-16 | MRSN | Mersana Therapeutics, Inc. | Huber Martin H. Jr. | Pres, CEO | S - Sale+OE | $0.58 | -4,514 | 122,875 | -4% | -$2,618 | |||||
| D | 2025-01-16 | MRSN | Mersana Therapeutics, Inc. | Deschuytner Brian | SVP, COO, CFO | S - Sale+OE | $0.58 | -8,470 | 121,393 | -7% | -$4,913 | |||||
| D | 2025-01-16 | MRSN | Mersana Therapeutics, Inc. | Carvajal Alejandra | SVP, GC | S - Sale+OE | $0.58 | -5,096 | 78,296 | -6% | -$2,956 | |||||
| D | 2025-01-16 | MRSN | Mersana Therapeutics, Inc. | Bala Mohan | SVP, Chief Development Officer | S - Sale+OE | $0.58 | -5,939 | 68,872 | -8% | -$3,445 | |||||
2025-01-17 | MDGL | Madrigal Pharmaceuticals, Inc. | Kelley Shannon T | GC | S - Sale | $273.41 | -277 | 7,705 | -3% | -$75,735 | ||||||
2025-01-17 | MDGL | Madrigal Pharmaceuticals, Inc. | Waltermire Robert E. | SVP, Chief Pharma Dev. | S - Sale | $273.41 | -442 | 5,058 | -8% | -$120,847 | ||||||
2025-01-17 | MDGL | Madrigal Pharmaceuticals, Inc. | Taub Rebecca | Pres, R, D,, CMO | S - Sale | $273.41 | -1,689 | 1,112,850 | 0% | -$461,789 | ||||||
2025-01-15 | OSTX | Os Therapies Inc | Auerbach Shalom | 10% | S - Sale | $6.74 | -16,720 | 2,554,582 | -1% | -$112,609 | ||||||
2025-01-15 | IGMS | Igm Biosciences, Inc. | Weber Steven | Principal Accounting Officer | S - Sale | $1.70 | -1,122 | 30,582 | -4% | -$1,907 | ||||||
2025-01-16 | PTGX | Protagonist Therapeutics, Inc | Molina Arturo Md | Chief Medical Officer | S - Sale | $0.00 | -3,640 | 83,892 | -4% | -$0 | ||||||
2025-01-16 | PTGX | Protagonist Therapeutics, Inc | Ali Asif | CFO | S - Sale | $0.00 | -3,918 | 62,821 | -6% | -$0 | ||||||
2025-01-15 | NKTX | Nkarta, Inc. | Shook David | See Remarks | S - Sale | $2.20 | -8,638 | 190,955 | -4% | -$19,004 | ||||||
2025-01-15 | NKTX | Nkarta, Inc. | Levin Alyssa | See Remarks | S - Sale | $2.20 | -5,838 | 102,662 | -5% | -$12,844 | ||||||
2025-01-15 | NKTX | Nkarta, Inc. | Brandenberger Ralph | Chief Technical Officer | S - Sale | $2.20 | -7,447 | 124,796 | -6% | -$16,383 | ||||||
2025-01-15 | NKTX | Nkarta, Inc. | Hastings Paul J | CEO | S - Sale | $2.20 | -17,378 | 319,859 | -5% | -$38,232 | ||||||
2025-01-15 | NKTX | Nkarta, Inc. | Hager Alicia J. | GC | S - Sale | $2.20 | -9,584 | 146,735 | -6% | -$21,085 | ||||||
2025-01-17 | OPK | Opko Health, Inc. | Frost Phillip Md Et Al | CEO, COB, 10% | P - Purchase | $1.47 | +150,000 | 246,882,605 | 0% | +$220,425 | ||||||
| D | 2025-01-15 | NUVL | Nuvalent, Inc. | Porter James Richard | Pres, CEO | S - Sale+OE | $75.99 | -27,000 | 249,062 | -10% | -$2,051,777 | |||||
| D | 2025-01-15 | CNTA | Centessa Pharmaceuticals Plc | Hussain Iqbal J | GC | S - Sale+OE | $15.29 | -6,000 | 123,765 | -5% | -$91,740 | |||||
2025-01-15 | ETNB | 89Bio, Inc. | Le-Nguyen Quoc | See Remarks | S - Sale | $6.49 | -10,963 | 271,833 | -4% | -$71,150 | ||||||
| AM | 2025-01-15 | AVIR | Atea Pharmaceuticals, Inc. | Berger Franklin M | Dir | P - Purchase | $3.26 | +25,000 | 476,897 | +6% | +$81,499 | |||||
2025-01-17 | ANIX | Anixa Biosciences Inc | Titterton Lewis H Jr | Dir | P - Purchase | $2.57 | +10,000 | 922,334 | +1% | +$25,700 | ||||||
| M | 2025-01-15 | AVIR | Atea Pharmaceuticals, Inc. | Berger Franklin M | Dir | P - Purchase | $3.26 | +25,000 | 476,897 | +6% | +$81,499 | |||||
| M | 2024-12-27 | ETST | Earth Science Tech, Inc. | Saumat Giorgio R. | CEO, 10% | P - Purchase | $0.20 | +787,500 | 122,680,127 | +1% | +$155,757 | |||||
2025-01-15 | VYNE | Vyne Therapeutics Inc. | Lepore Patrick G | Dir | P - Purchase | $2.92 | +15,000 | 51,472 | +41% | +$43,800 | ||||||
| D | 2025-01-15 | MRSN | Mersana Therapeutics, Inc. | Protopapas Anna | Dir | S - Sale+OE | $0.63 | -6,191 | 467,935 | -1% | -$3,900 | |||||
| D | 2025-01-15 | MRSN | Mersana Therapeutics, Inc. | Mandelia Ashish | VP, Chief Accounting Officer | S - Sale+OE | $0.63 | -1,791 | 52,388 | -3% | -$1,128 | |||||
| D | 2025-01-15 | MRSN | Mersana Therapeutics, Inc. | Lowinger Timothy B | SVP, Chief Sci., Tech. Officer | S - Sale+OE | $0.63 | -1,794 | 245,930 | -1% | -$1,130 | |||||
| D | 2025-01-15 | MRSN | Mersana Therapeutics, Inc. | Deschuytner Brian | SVP, COO, CFO | S - Sale+OE | $0.63 | -2,331 | 109,030 | -2% | -$1,469 | |||||
| D | 2025-01-15 | MRSN | Mersana Therapeutics, Inc. | Carvajal Alejandra | SVP, GC | S - Sale+OE | $0.63 | -952 | 70,892 | -1% | -$600 | |||||
2025-01-14 | INSM | Insmed Inc | Flammer Martina M.D. | Chief Medical Officer | S - Sale | $68.72 | -1,384 | 100,165 | -1% | -$95,108 | ||||||
2025-01-14 | INSM | Insmed Inc | Adsett Roger | COO | S - Sale | $68.72 | -1,457 | 146,082 | -1% | -$100,125 | ||||||
2025-01-14 | INSM | Insmed Inc | Schaeffer Orlov S Nicole | Chief People Strategy Officer | S - Sale | $68.72 | -872 | 97,083 | -1% | -$59,924 | ||||||
| D | 2025-01-15 | INSM | Insmed Inc | Lewis William | Chair, CEO | S - Sale+OE | $70.18 | -38,635 | 663,958 | -5% | -$2,711,456 | |||||
| D | 2025-01-15 | HRMY | Harmony Biosciences Holdings, Inc. | Dierks Jeffrey | CHIEF COMMERCIAL OFFICER | S - Sale+OE | $37.01 | -10,507 | 0 | -100% | -$388,841 | |||||
| M | 2025-01-14 | GYRE | Gyre Therapeutics, Inc. | Ma Songjiang | Pres | S - Sale | $10.62 | -4,000 | 2,911,138 | 0% | -$42,480 | |||||
2025-01-13 | MLYS | Mineralys Therapeutics, Inc. | Levy Adam Scott | CFO, Secretary | S - Sale | $9.10 | -10,757 | 226,097 | -5% | -$97,864 | ||||||
2025-01-13 | MLYS | Mineralys Therapeutics, Inc. | Congleton Jon | CEO | S - Sale | $9.06 | -18,333 | 877,608 | -2% | -$166,082 | ||||||
| D | 2025-01-14 | MRSN | Mersana Therapeutics, Inc. | Protopapas Anna | Dir | S - Sale+OE | $0.66 | -11,534 | 457,376 | -2% | -$7,612 | |||||
| D | 2025-01-14 | MRSN | Mersana Therapeutics, Inc. | Mandelia Ashish | VP, Chief Accounting Officer | S - Sale+OE | $0.66 | -1,007 | 49,396 | -2% | -$665 | |||||
| D | 2025-01-14 | MRSN | Mersana Therapeutics, Inc. | Lowinger Timothy B | SVP, Chief Sci., Tech. Officer | S - Sale+OE | $0.66 | -3,483 | 242,932 | -1% | -$2,299 | |||||
| D | 2025-01-14 | MRSN | Mersana Therapeutics, Inc. | Deschuytner Brian | SVP, COO, CFO | S - Sale+OE | $0.66 | -3,713 | 105,111 | -3% | -$2,451 | |||||
| D | 2025-01-14 | MRSN | Mersana Therapeutics, Inc. | Carvajal Alejandra | SVP, GC | S - Sale+OE | $0.66 | -3,330 | 69,344 | -5% | -$2,198 | |||||
| D | 2025-01-14 | MRSN | Mersana Therapeutics, Inc. | Bala Mohan | SVP, Chief Development Officer | S - Sale+OE | $0.66 | -3,253 | 60,228 | -5% | -$2,147 | |||||
| M | 2025-01-13 | ZYME | Zymeworks Inc. | Ecor1 Capital, LLC | Dir, 10% | P - Purchase | $13.59 | +167,654 | 15,578,732 | +1% | +$2,278,811 | |||||
| D | 2025-01-13 | BPMC | Blueprint Medicines Corp | Albers Jeffrey W. | Dir | S - Sale+OE | $102.28 | -5,000 | 157,557 | -3% | -$511,400 | |||||
| D | 2025-01-13 | BPMC | Blueprint Medicines Corp | Hurley Ariel | Principal Accounting Officer | S - Sale+OE | $100.00 | -2,250 | 14,967 | -13% | -$225,000 | |||||
2025-01-15 | OPK | Opko Health, Inc. | Frost Phillip Md Et Al | CEO, COB, 10% | P - Purchase | $1.48 | +500,000 | 246,732,605 | 0% | +$740,850 | ||||||
| M | 2025-01-13 | RGLS | Regulus Therapeutics Inc. | Aker Christopher Ray | SVP, GC | S - Sale | $1.26 | -43,635 | 49,546 | -47% | -$55,120 | |||||
| M | 2025-01-13 | RGLS | Regulus Therapeutics Inc. | Hagan Joseph P | CEO | S - Sale | $1.26 | -127,054 | 210,808 | -38% | -$160,495 | |||||
| M | 2025-01-13 | RGLS | Regulus Therapeutics Inc. | Calsada Crispina | CFO | S - Sale | $1.26 | -43,804 | 45,478 | -49% | -$55,333 | |||||
2025-01-13 | RGLS | Regulus Therapeutics Inc. | Klassen Preston | Pres, Head of R, D | S - Sale | $1.26 | -31,445 | 36,055 | -47% | -$39,721 | ||||||
| D | 2025-01-13 | KNSA | Kiniksa Pharmaceuticals International, Plc | Tessari Eben | COO | S - Sale+OE | $18.24 | -14,000 | 88,975 | -14% | -$255,413 | |||||
2025-01-13 | IMVT | Immunovant, Inc. | Roivant Sciences Ltd. | Dir, 10% | P - Purchase | $20.00 | +16,845,010 | 96,650,341 | +21% | +$336,900,200 | ||||||
| D | 2025-01-13 | HRMY | Harmony Biosciences Holdings, Inc. | Dierks Jeffrey | CHIEF COMMERCIAL OFFICER | S - Sale+OE | $37.04 | -7,180 | 0 | -100% | -$265,946 | |||||
| M | 2025-01-13 | RNAC | Cartesian Therapeutics, Inc. | Springer Timothy A | Dir, 10% | P - Purchase | $17.47 | +20,967 | 9,391,955 | 0% | +$366,354 | |||||
2025-01-15 | ANIX | Anixa Biosciences Inc | Kumar Amit | CEO | P - Purchase | $2.23 | +43,000 | 559,925 | +8% | +$95,890 | ||||||
2025-01-15 | ANIX | Anixa Biosciences Inc | Catelani Michael | Pres, COO, CFO | P - Purchase | $2.15 | +9,289 | 44,500 | +26% | +$19,971 | ||||||
2025-01-14 | COGT | Cogent Biosciences, Inc. | Pinnow Cole | Chief Commercial Officer | P - Purchase | $7.60 | +43,750 | 45,848 | >999% | +$332,413 | ||||||
| D | 2025-01-10 | CORT | Corcept Therapeutics Inc | Swisher Daniel N Jr | Dir | S - Sale+OE | $50.54 | -2,200 | 0 | -100% | -$111,188 | |||||
| D | 2025-01-14 | LQDA | Liquidia Corp | Schundler Russell | GC | S - Sale+OE | $11.78 | -16,393 | 587,978 | -3% | -$193,110 | |||||
| D | 2025-01-14 | LQDA | Liquidia Corp | Saggar Rajeev | Chief Medical Officer | S - Sale+OE | $11.78 | -6,249 | 270,388 | -2% | -$73,613 | |||||
| D | 2025-01-14 | LQDA | Liquidia Corp | Moomaw Scott | Chief Commercial Officer | S - Sale+OE | $11.78 | -8,362 | 215,494 | -4% | -$98,504 | |||||
| D | 2025-01-14 | LQDA | Liquidia Corp | Kaseta Michael | CFO, COO | S - Sale+OE | $11.78 | -23,370 | 401,755 | -5% | -$275,299 | |||||
| D | 2025-01-14 | LQDA | Liquidia Corp | Adair Jason | Chief Business Officer | S - Sale+OE | $11.78 | -4,809 | 180,215 | -3% | -$56,650 | |||||
| D | 2025-01-14 | LQDA | Liquidia Corp | Jeffs Roger | CEO | S - Sale+OE | $11.78 | -22,343 | 2,607,439 | -1% | -$263,201 | |||||
| D | 2025-01-13 | UTHR | United Therapeutics Corp | Benkowitz Michael | Pres, COO | S - Sale+OE | $364.62 | -10,000 | 2,577 | -80% | -$3,646,223 | |||||
2025-01-13 | APLS | Apellis Pharmaceuticals, Inc. | Watson David O. | GC | S - Sale | $28.70 | -4,965 | 187,892 | -3% | -$142,506 | ||||||
2025-01-13 | VSTM | Verastem, Inc. | Paterson Dan | Pres, CEO | S - Sale | $5.24 | -8,568 | 347,581 | -2% | -$44,896 | ||||||
2025-01-13 | APLS | Apellis Pharmaceuticals, Inc. | Townsend Adam J. | Chief Commercial Officer | S - Sale | $28.70 | -2,685 | 90,269 | -3% | -$77,065 | ||||||
2025-01-13 | APLS | Apellis Pharmaceuticals, Inc. | Sullivan Timothy Eugene | CFO | S - Sale | $28.70 | -2,170 | 158,496 | -1% | -$62,284 | ||||||
2025-01-13 | AVDL | Avadel Pharmaceuticals Plc | Thornton Peter J. | Dir | P - Purchase | $8.05 | +10,000 | 104,055 | +11% | +$80,450 | ||||||
2025-01-13 | AVDL | Avadel Pharmaceuticals Plc | Ende Eric J | Dir | P - Purchase | $7.84 | +30,000 | 208,900 | +17% | +$235,218 | ||||||
2025-01-13 | APLS | Apellis Pharmaceuticals, Inc. | Nicholson Nur | Chief Technical Officer | S - Sale | $28.70 | -2,632 | 54,156 | -5% | -$75,544 | ||||||
2025-01-13 | APLS | Apellis Pharmaceuticals, Inc. | Lewis Karen | Chief People Officer | S - Sale | $28.70 | -1,599 | 45,099 | -3% | -$45,895 | ||||||
2025-01-13 | APLS | Apellis Pharmaceuticals, Inc. | Francois Cedric | CEO | S - Sale | $28.70 | -6,247 | 1,846,837 | 0% | -$179,302 | ||||||
2025-01-13 | APLS | Apellis Pharmaceuticals, Inc. | Eisele Jeffrey | Chief Development Officer | S - Sale | $28.70 | -264 | 56,881 | 0% | -$7,577 | ||||||
2025-01-13 | APLS | Apellis Pharmaceuticals, Inc. | Deschatelets Pascal | Chief Scientific Officer | S - Sale | $28.70 | -2,288 | 1,138,195 | 0% | -$65,670 | ||||||
| D | 2025-01-10 | COLL | Collegium Pharmaceutical, Inc | Kuhlmann Shirley R. | EVP, GC | S - Sale+OE | $33.04 | -27,500 | 119,184 | -19% | -$908,628 | |||||
2025-01-13 | APLS | Apellis Pharmaceuticals, Inc. | Delong Mark Jeffrey | Chief Business, Strat Officer | S - Sale | $28.70 | -1,599 | 58,796 | -3% | -$45,895 | ||||||
2025-01-13 | APLS | Apellis Pharmaceuticals, Inc. | Chopas James George | VP, Chief Accounting Officer | S - Sale | $28.70 | -783 | 37,358 | -2% | -$22,474 | ||||||
| M | 2025-01-10 | GBIO | Generation Bio Co. | Quinn Anthony G. | Dir | P - Purchase | $0.96 | +210,791 | 299,286 | +238% | +$203,209 | |||||
| M | 2025-01-10 | GYRE | Gyre Therapeutics, Inc. | Ma Songjiang | Pres | S - Sale | $10.02 | -1,113 | 2,915,138 | 0% | -$11,157 | |||||
| D | 2025-01-10 | CDMO | Avid Bioservices, Inc. | Richieri Richard A. | Chief Operations Officer | S - Sale+OE | $12.37 | -2,483 | 58,320 | -4% | -$30,715 | |||||
| D | 2025-01-08 | OLMA | Olema Pharmaceuticals, Inc. | Bain Capital Life Sciences Investors, LLC | 10% | P - Purchase | $5.76 | +300,000 | 4,300,000 | +8% | +$1,727,370 | |||||
2025-01-10 | IBIO | Ibio, Inc. | Duran Felipe | CFO | P - Purchase | $2.72 | +9,191 | 11,139 | +472% | +$25,000 | ||||||
2025-01-10 | IBIO | Ibio, Inc. | Brenner Martin | See Remarks | P - Purchase | $2.72 | +9,191 | 18,316 | +101% | +$25,000 | ||||||
2025-01-10 | IBIO | Ibio, Inc. | Banjak Marc | GC | P - Purchase | $2.72 | +9,191 | 11,066 | +490% | +$25,000 |
| A | Amended filing |
| D | Derivative transaction in filing (usually option exercise) |
| E | Error detected in filing |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |